AIDSWEEKLY Plus; Monday, November 22, 2004
Staff Medical Writers

According to recent research published in the journal AIDS, "Since 2001, the unrestricted use of HIVNET012 has been recommended for the prevention of mother-to-child transmission in low-resource settings, despite the lack of validated efficacy data outside research settings.

"We implemented the nevirapine regimen in a real-life situation in Kenya," wrote A. Quaghebeur and coauthors.

"The perinatal HIV-1 transmission rate at 14 weeks was 18.1%," said researchers, "similar to the 21.7% before the intervention."

"These data call for further evaluation of the simple nevirapine regimen in field conditions, and underline the need for alternative strategies," scientists concluded.

Quaghebeur and colleagues published their study in AIDS (Low efficacy of nevirapine (HIVNET012) in preventing perinatal HIVA transmission in a real-life situation. AIDS. 2004 Sep 3;18(13):1854-6.

For additional information, contact A. Quaghebeur, State University Ghent, International Center Reproductive Hlth, B-9000 Ghent, Belgium.

The publisher's contact information for the journal AIDS is: Lippincott Williams & Wilkins, 530 Walnut St., Philadelphia, PA 19106-3621, USA.

The information in this article comes under the major subject areas of HIV/AIDS, Mother-to-Child Transmission, Epidemiology, and HIV Prevention.

This article was prepared by AIDS Weekly editors from staff and other reports

Reference

Quaghebeur A, Mutunga L, Mwanyumba F, et al., "Low efficacy of nevirapine (HIVNET012) in preventing perinatal HIV-1 transmission in a real-life situation", AIDS. 2004 Sep 3;18(13):1854-6.

PubMED Related articles Search

041122
AW041111

Copyright © 2004 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.